gms | German Medical Science

71. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
9. Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

21.06. - 24.06.2020

Article

Send article

MiRNA-181a regulates IDH1 expression in glioblastoma and is a prognostic marker for the clinical course of the disease

Die miRNA-181a reguliert die IDH1 Expression im Glioblastom und dient als prognostischer Marker für den klinischen Verlauf der Erkrankung

Meeting Abstract

Search Medline for

  • presenting/speaker Christoph Sippl - Universitätsklinikum des Saarlandes, Neuropathologie, Homburg, Deutschland
  • Schoeneberger Louisa - Universitätsklinikum des Saarlandes, Klinik für Neurochirurgie, Homburg, Deutschland
  • Ralf Ketter - Universitätsklinikum des Saarlandes, Klinik für Neurochirurgie, Homburg, Deutschland
  • Steffi Urbschat - Universitätsklinikum des Saarlandes, Klinik für Neurochirurgie, Homburg, Deutschland
  • Joachim Oertel - Universitätsklinikum des Saarlandes, Klinik für Neurochirurgie, Homburg, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 71. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 9. Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie. sine loco [digital], 21.-24.06.2020. Düsseldorf: German Medical Science GMS Publishing House; 2020. DocP160

doi: 10.3205/20dgnc443, urn:nbn:de:0183-20dgnc4434

Published: June 26, 2020

© 2020 Sippl et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: The prognosis of WHO grade IV gliomas is still very poor. IDH1 mutation plays a crucial role in prognosis of high grade Glioma. Patient with a mutation (R132H) in the IDH1 gene show an ameliorated overall survival. In previously published literature miRNA-181a was identified as a regulator of IDH1 expression. This study therefore evaluates the expression of miRNA-181a as a potential prognostic marker in glioblastoma.

Methods: Using qRT-PCR, 74 GBM specimens were analysed for the expression of miRNA-181a calculated as fold change (FC). The results of the analysis were correlated with individual clinical data. All further molecular and clinical characteristics like MGMT-Methylation, extent of resection and Karnofsky-Index were considered.

Results: In the cohort at hand 11/74 (14,9%) patients displayed an IDH1 mutation. 69/74 (85,1%) showed an IDH1 wild type. Patients with an IDH1 mutation showed a significantly longer overall survival (p = 0.004). Expression of miRNA-181a (FC) was significantly higher in patients harbouring an IDH1 mutation (p = 0.004). In patients with IDH1 wild type expression high miRNA-181a expression is significantly prognostic of a more favourable clinical course with increased overall survival (p=0.019). This effect was not observable in patients with an IDH1 mutation.

Conclusion: The miRNA-181a seems to be a promising prognostic marker in glioblastoma patients with IDH1 wild type characteristics and should be further evaluated.